Related Experiment Video
Updated: Oct 10, 2026
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
Allelic deletions of cell growth regulators during progression of bladder cancer
H Primdahl1, H von der Maase, M Christensen
1Department of Clinical Biochemistry, Aarhus University Hospital, Denmark.
Abstract:
Cell growth regulators include proteins of the p53 pathway encoded by the genes CDKN2A (p16, p14arf), MDM2, TP53, and CDKN1A (p21) as well as proteins encoded by genes like RB1, E2F, and MYCL. In the present study we investigated allelic deletions of all these genes in each recurrent bladder tumor from well-defined clinical material with more than 3 years of follow-up. We followed three groups (22 or 23 patients/group) of patients with: (a) recurrent noninvasive tumors (Ta); (b) primary muscle-invasive tumors (T2-T4); and (c) progressing tumors (Ta/T1 --> T2/T4). We found a significant difference in the numbers of gene loci hit by deletions muscle-invasive versus noninvasive tumors (P = 0.0000002), with the genes most often hit by deletions in muscle-invasive tumors being TP53, RB1, and MYCL. A number of novel findings were made. Losses of MYCL and RB1 alleles were more pronounced in patients having concomitant field disease because 11 of 14 informative cases showed losses compared with 3 of 8 cases without field disease. A more pronounced deletion of TP53 (P = 0.002) and RB1 (P = 0.02) was found in the progressing tumor group compared with the recurrent noninvasive group, and, finally, the combined loss of TP53 and RB1 was present only in the progressing tumor or muscle-invasive groups. Deletion of two or more loci in TP53, MYCL, RB1, and CDKN2A was found in 10 patients in the progressing tumor group and in only 1 patient in the recurrent noninvasive group (P = 0.004). The data demonstrate that a characteristic difference between recurrent noninvasive and recurrent progressing bladder tumors is loss of cell cycle-regulatory genes in the latter group.
Insights
Recurrent bladder tumors show distinct genetic differences. Progressing tumors, unlike noninvasive ones, frequently lose cell cycle-regulatory genes, particularly TP53 and RB1, indicating their role in tumor progression.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Cell cycle regulators, including p53 pathway proteins (encoded by CDKN2A, MDM2, TP53, CDKN1A) and others (RB1, E2F, MYCL), are crucial for controlling cell growth.
- Understanding genetic alterations in these regulators is vital for diagnosing and treating bladder cancer, especially recurrent forms.
Purpose of the Study:
- To investigate allelic deletions in key cell cycle regulatory genes in different groups of recurrent bladder tumors.
- To identify genetic differences between noninvasive, muscle-invasive, and progressing bladder tumors.
Main Methods:
- Analysis of allelic deletions in genes like CDKN2A, MDM2, TP53, CDKN1A, RB1, E2F, and MYCL.
- Comparison of deletion frequencies across three patient groups: recurrent noninvasive (Ta), primary muscle-invasive (T2-T4), and progressing (Ta/T1 to T2/T4) bladder tumors.
- Statistical analysis to determine the significance of observed differences.
Main Results:
- Significant differences in gene deletions were observed between muscle-invasive and noninvasive bladder tumors (P = 0.0000002).
- TP53, RB1, and MYCL were most frequently deleted in muscle-invasive tumors.
- Progressing tumors showed more pronounced deletions of TP53 (P = 0.002) and RB1 (P = 0.02) compared to recurrent noninvasive tumors.
- Combined loss of TP53 and RB1 was specific to progressing or muscle-invasive groups.
- Deletion of two or more key loci (TP53, MYCL, RB1, CDKN2A) was significantly higher in progressing tumors (10/group) versus noninvasive tumors (1/group) (P = 0.004).
Conclusions:
- Loss of cell cycle-regulatory genes is a characteristic distinction between recurrent noninvasive and recurrent progressing bladder tumors.
- These genetic alterations, particularly in TP53 and RB1, are associated with bladder tumor progression and invasiveness.
Related Concept Videos
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...